The Emerging Market for Medical Psilocybin in the United States

Psilocybin, the psychoactive compound found in certain mushrooms, is beginning to transition from a federally prohibited substance to a regulated therapeutic modality at the state level in the United States. While it remains classified as a Schedule I substance under the Controlled Substances Act, clinical research, state level legalization, and investor interest are driving the early formation of a new healthcare market.

For retail insurance agents, this represents the emergence of a specialized and complex category of healthcare professional liability (HPL) risk. Similar to the early development of ketamine clinics and transcranial magnetic stimulation (TMS) services, psilocybin treatment exists within a fragmented regulatory environment, evolving clinical standards, and limited insurance precedent.

This article explains what medical psilocybin is, how regulated programs are structured, the size and trajectory of the market, and the insurance challenges associated with placing coverage for these risks.

PART 1: Understanding Medical Psilocybin and Its Regulatory Path

What Is Psilocybin in a Medical Context?

Psilocybin is a naturally occurring psychedelic compound that affects perception, cognition, and mood. Modern clinical research has focused on its potential to treat [1]:

• Treatment resistant depression
• Post traumatic stress disorder (PTSD)
• Anxiety associated with terminal illness
• Substance use disorders

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to psilocybin assisted therapy for major depressive disorder, indicating strong preliminary evidence of clinical benefit and an accelerated review pathway[2]. Clinical trials conducted by institutions such as Johns Hopkins University have shown that supervised psilocybin sessions, combined with psychotherapy, can produce significant and sustained reductions in depressive symptoms[3].

Despite this progress, psilocybin remains federally illegal outside of approved research settings, creating a regulatory disconnect between clinical advancement and legal status.

State Level Legalization and Program Structures

In the absence of federal legalization, psilocybin access is currently being developed through state level frameworks.

Oregon Psilocybin Services (OPS):

• • • Established through Measure 109 in 2020.

    • Fully implemented in 2023 under the Oregon Health Authority.

    • Allows licensed facilities to administer psilocybin in supervised settings.

    • Does not require a medical diagnosis or physician prescription.

Under this model, psilocybin is delivered as a facilitated service, not a traditional prescription drug[4].

Other Jurisdictions Following Similar Paths:

• • • Colorado passed Proposition 122, creating a regulated natural medicine program with phased implementation through the late 2020s[5].

    • Several municipalities, including Oakland, Santa Cruz, and Washington D.C. have decriminalized psilocybin [6].

This patchwork regulatory environment means that psilocybin services are highly jurisdiction specific, with significant variation in licensing, oversight, and operational requirements.

How Psilocybin Services Are Delivered

Because psilocybin therapy is not currently recognized or regulated at a federal level, treatment can vary dramatically by district or region. However, Oregon Psilocybin Services provides us with an example of what a regulated environment may look like. Following OPS regulations, treatment is structured as a multi-phase process rather than a single clinical encounter[7]:

1. Screening and Intake - Evaluation for medical and psychological suitability, including identification of contraindications.
2. Preparation Sessions - Facilitators establish expectations and therapeutic goals.
3. Administration Session - Psilocybin is administered on site under supervision, with sessions lasting 4 to 8 hours.
4. Integration Sessions - Follow up meetings to process and apply the experience.

Facilities providing these services are commonly referred to as psilocybin service centers or psychedelic therapy clinics. Staffing models generally include licensed or certified facilitators, with varying levels of medical oversight depending on state regulations.

PART 2: Market Size, Growth, and Investment Trends

Current Market Size and Projections

Although the regulated U.S. psilocybin market is still in its early stages, broader psychedelic therapy data provides insight into its trajectory.

Grand View Research estimated the global psychedelic drugs market at approximately $3.6 billion in 2023, with a projected compound annual growth rate exceeding 15 percent through 2030[8]. North America is expected to lead early adoption due to regulatory experimentation and concentration of clinical research.

While current revenue from psilocybin services is limited to early adopter states like Oregon, expansion into additional jurisdictions is expected to drive rapid growth over the next decade.

Key Drivers of Market Growth

1. Rising Mental Health Demand

The prevalence of depression, anxiety, and substance use disorders continues to increase, creating demand for alternative therapies[9].

2. Clinical Validation

Peer reviewed research and FDA designations are strengthening the credibility of psilocybin as a therapeutic tool[10][11].

3. Regulatory Momentum

State level legalization efforts are creating pathways for legal operation despite federal restrictions[12][13].

4. Cash Pay Model

Most psilocybin services are currently paid out of pocket, with session costs often ranging from $2,000 to $5,000, reducing reliance on traditional reimbursement structures[14].

5. Investor Interest

Venture capital and private equity firms are actively investing in psychedelic therapy platforms, clinic operators, and drug development companies[15][16].

PART 3: Insurance Challenges in a Federally Illegal but State Legal Market

Why Psilocybin Creates Unique Insurance Complexity

Psilocybin presents a set of challenges not typically found in traditional healthcare risks:

1. Federal Illegality - Psilocybin remains a Schedule I substance under federal law, even where state programs allow its use[17].
2. Limited Carrier Appetite - Many admitted carriers exclude coverage for federally illegal activities.
3. Evolving Standards of Care - Clinical protocols are still developing, making malpractice exposure difficult to quantify.
4. Non-Traditional Delivery Model - Extended sessions and altered patient consciousness create unique liability considerations.

As a result, most placements occur in the surplus lines market.

Key Insurance Coverages and Risk Considerations

Healthcare Professional Liability (HPL)

Primary exposure arises from:

• • • Improper screening or failure to identify contraindications

    • Adverse psychological reactions

    • Inadequate supervision during sessions

    • Failure in post session integration

Because standards of care are still evolving, underwriters place significant emphasis on protocols and training.

General Liability

Covers premises related risks, including:

• • • Client injury during treatment sessions

    • Slip and fall incidents

    • Property damage

Extended session duration and altered states increase supervision related exposure.

Errors and Omissions (E&O)

Applies to:

• • • Administrative failures

    • Misrepresentation of services

    • Regulatory noncompliance

Directors and Officers (D&O) Liability

Important for investor backed organizations. Exposure includes:

• • • Governance failures

    • Regulatory violations

    • Misrepresentation to investors

Cyber Liability

Psilocybin providers manage sensitive behavioral health data, creating exposure to:

• • • Data breaches

    • HIPAA related liabilities (where applicable)

    • Ransomware attacks

Underwriting Considerations

Underwriters evaluating psilocybin risks typically require detailed information on:

• State licensing and regulatory compliance
• Facilitator training and certification
• Clinical protocols for screening and administration
• Emergency response procedures
• Facility layout and supervision capabilities
• Informed consent and documentation practices

Given the novelty of the risk, underwriting scrutiny is often significantly higher than for traditional outpatient healthcare providers.

PART 4: What This Means for Retail Insurance Agents

Psilocybin Is a Distinct Risk Category

Psilocybin providers cannot be underwritten as standard behavioral health practices. Their exposure includes:

• • Controlled substance liability

  • Extended patient interaction periods

  • Altered patient cognition

  • Emerging regulatory oversight

Standard policies are often insufficient or misaligned with actual operations.

Coverage Gaps Are Likely

Many insureds:

• • Do not fully understand their risk profile

  • Carry policies with exclusions for key exposures

  • Work with carriers unfamiliar with psychedelic services

This creates both client risk and potential E&O exposure for retail agents.

Early Expertise Creates Opportunity

As the market grows, agents who understand:

• • Regulatory frameworks

  • Clinical delivery models

  • Carrier appetite

Will be positioned to lead in a specialized, high growth segment of healthcare insurance.

Conclusion

Medical psilocybin is in the early stages of becoming a regulated healthcare service in the United States. While federal legality remains unresolved, state level programs, clinical validation, and market demand are driving rapid development.

For retail insurance agents, this presents both complexity and opportunity. The regulatory environment is fragmented, underwriting is specialized, and standard coverage solutions are often inadequate. However, agents who develop expertise in this space can position themselves at the forefront of a growing and underserved market.

Understanding the risk now is the first step toward placing it effectively as the market matures.

How Ethos Supports Retail Insurance Agents in Emerging Healthcare Markets

Psilocybin services are part of a broader shift toward new behavioral health treatment models. These risks require specialized underwriting knowledge and access to appropriate carriers.

Ethos Insurance Partners works with retail insurance agents to:

• Evaluate complex healthcare service models.
• Identify coverage gaps tied to emerging treatments.
• Structure coordinated insurance programs across HPL, general liability, D&O, and cyber.
• Access carriers with appetite for non-traditional healthcare risks.
• Support submissions with underwriting ready documentation.

Our goal is to help you place coverage that aligns with how these businesses actually operate.

The market is active, growing, and underserved. Don’t wait. Click to Call, Email, or Schedule a Meeting now! 

Sources

[1] Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review

https://pmc.ncbi.nlm.nih.gov/articles/PMC8901083/

[2] [10] Psychedelics: Threshold of a Therapeutic Revolution

https://pubmed.ncbi.nlm.nih.gov/37247807/

[3] [11] Psilocybin Treatment for Major Depression Effective for Up to a Year for Most Patients, Study Shows

https://www.hopkinsmedicine.org/news/newsroom/news-releases/2022/02/psilocybin-treatment-for-major-depression-effective-for-up-to-a-year-for-most-patients-study-shows

[4] [12] Oregon Health Authority – Oregon Psilocybin Services

https://www.oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx

[5] [13] Natural Medicine Division Newsroom - Colorado

https://dnm.colorado.gov/natural-medicine-frequently-asked-questions

[6] Psychedelics Legalization & Decriminalization Tracker

https://psychedelicalpha.com/resources/psychedelic-laws/

[7] The Perilous Policy of Oregon's Psilocybin Services

https://jaapl.org/content/51/2/160

[8] Psychedelic Drugs Market Size, Share & Growth Report 2030

https://www.grandviewresearch.com/industry-analysis/psychedelic-drugs-market-report

[9] Mental Health Issues Increased Significantly in Young Adults Over Last Decade

https://www.apa.org/news/press/releases/2019/03/mental-health-adults

[14] Oregon Psilocybin Therapy Clients Tend to be Wealthier, New Data Suggests

https://www.klcc.org/health-medicine/2025-07-02/oregon-psilocybin-therapy-clients-tend-to-be-wealthier-new-data-suggests

[15] PE Plays It Safe in Psychedelic Investments While Venture Goes Bold

https://bhbusiness.com/2025/08/18/pe-plays-it-safe-in-psychedelic-investments-while-venture-goes-bold/

[16] Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry

https://pmc.ncbi.nlm.nih.gov/articles/PMC11661494/

[17] Controlled Substances - Alphabetical Order - SUBSTANCE CSCN CSA SCH NARC

https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf